EGFR mutations in exons 18-21 in sporadic breast cancer

被引：27

作者：

Generali, D.

Leek, R.

Fox, S. B.

Moore, J. W.

Taylor, C.

Chambers, P.

Harris, A. L. ^{[1
]}

机构：

[1] Weatherall Inst Mol Med, Mol Oncol Labs, Oxford, England

[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] St James Univ Hosp, CRUK, Mutat Detect Facil, Leeds, W Yorkshire, England

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷 / 01期

关键词：

D O I：

10.1093/annonc/mdl322

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：203 / U7

页数：3

共 6 条

[1]

BASELGA J, 2005, J CLIN ONCOL

[2] EGFR gene amplification in breast cancer:: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations [J].

Bhargava, R ;

Gerald, WL ;

Li, AR ;

Pan, QL ;

Lal, P ;

Ladanyi, M ;

Chen, BY .

MODERN PATHOLOGY, 2005, 18 (08) :1027-1033

[3] Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas [J].

Lee, JW ;

Soung, YH ;

Seo, SH ;

Kim, SY ;

Park, CH ;

Wang, YP ;

Park, K ;

Nam, SW ;

Park, WS ;

Kim, SH ;

Lee, JY ;

Yoo, NJ ;

Lee, SH .

CLINICAL CANCER RESEARCH, 2006, 12 (01) :57-61

[4] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[5] Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial [J].

Polychronis, A ;

Sinnett, HD ;

Hadjiminas, D ;

Singhal, H ;

Monsi, JL ;

Shivapatham, D ;

Shousha, S ;

Jiang, J ;

Peston, D ;

Barrett, N ;

Vigushin, D ;

Morrison, K ;

Beresford, E ;

Ali, S ;

Slade, MJ ;

Coombes, RC .

LANCET ONCOLOGY, 2005, 6 (06) :383-391

[6] Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors [J].

Weber, F ;

Fukino, K ;

Sawada, T ;

Williams, N ;

Sweet, K ;

Brena, RM ;

Plass, C ;

Caldes, T ;

Mutter, GL ;

Villalona-Calero, MA ;

Eng, C .

BRITISH JOURNAL OF CANCER, 2005, 92 (10) :1922-1926

← 1 →